InvestorsHub Logo
Followers 4
Posts 479
Boards Moderated 0
Alias Born 01/03/2015

Re: frrol post# 212608

Friday, 01/12/2018 12:53:18 PM

Friday, January 12, 2018 12:53:18 PM

Post# of 403036
P is marketable. Key potential attributes : oral, inexpensive, early response, minimal side effects. Ph2b should answer questions on full effectiveness. So far at same stage of trials it is on par with Otezla. Question I have is if P shows dose escalating response effectiveness. Seems to be so.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News